Stringent Complete Response News Today

C4 Therapeutics, Inc. presented clinical data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of CFT7455, a MonoDAC?? degrader of IKZF1/3, for the potential treatment...

December 21, 2020 --Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population - -- Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen - -- First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 - -- FDA Approval Comes Approximately Three Mo...

(2) DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy --Oral ...